ClinicalTrials.gg
CompletedNCT02294461Updated Oct 24, 2025Results posted

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

A Phase 3 interventional study of Enzalutamide and Placebo in Progressive Metastatic Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 47 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2014, registered Nov 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Purpose of the study was to assess the effect of enzalutamide on time to Prostate Specific Antigen (PSA) progression as compared to placebo in chemotherapy naïve participants with progressive metastatic prostate cancer who have failed androgen deprivation therapy.

Read the detailed description

The study was a multinational Phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral enzalutamide (formerly MDV3100) in asymptomatic or mildly symptomatic participants with progressive metastatic prostate cancer who have disease progression despite androgen deprivation therapy. In order to join the study, participants could not have been previously treated with cytotoxic chemotherapy. Approximately 30 Chinese participants were allocated to the pharmacokinetic (PK) cohort. Participants in the PK cohort were required to be hospitalized from Day 1 before the randomization date to at least the completion of all the assessments planned on Day 3. All participants in the PK cohort underwent blood sampling for the PK analysis. Data reported in the results section was based on data cutoff dates of 20 Sept 2015 for efficacy and safety data and 20 Jan 2016 for PK outcome measures. The study completed double-blind period and is now in the open-label period.

02

Conditions studied

  • Progressive Metastatic Prostate Cancer

Keywords

  • Enzalutamide
  • Androgen receptor
  • Prostate cancer
  • Xtandi
03

In context

Bulbo-Spinal Atrophy, X-Linked

57 studies on the registry are indexed under Bulbo-Spinal Atrophy, X-Linked; 12 are open to participants now.

This study's enrollment of 395 is above the median of 42 across 42 interventional studies indexed under Bulbo-Spinal Atrophy, X-Linked.

Browse Bulbo-Spinal Atrophy, X-Linked studies →

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy
  • Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bone disease
  • No prior treatment with cytotoxic chemotherapy
  • Asymptomatic or mildly symptomatic from prostate cancer

Exclusion criteria

Exclusion Criteria:

  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
  • Known or suspected or active
  • History of another within the previous 5 years other than curatively treated non-melanomatous skin cancer
  • History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received 160 mg of enzalutamide orally once a day during double blind period until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer. Eligible participants who received enzalutamide during double blind and who provided consent to take part in open-label period continued to receive 160 mg of enzalutamide in open-label period orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.

    Drug: Enzalutamide

  • Experimental
    Placebo

    Participants received enzalutamide matching placebo orally once a day during double-blind period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.

    Drug: Placebo

  • Experimental
    Placebo followed by Enzalutamide

    Eligible participants who received enzalutamide matching placebo during double-blind period and who provided consent to take part in open-label period, received 160 mg of enzalutamide orally once a day during open-label period until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.

    Drug: Enzalutamide

Interventions

  • Oral

    Also known as: Xtandi, MDV3100

  • DrugPlacebo

    Oral

06

What researchers measure

Primary outcomes

  1. Time to Prostate-specific Antigen (PSA) Progression

    The time to Prostate Specific Antigen (PSA) progression was defined as the time from randomization to the PSA progression. The PSA progression was defined according to the consensus guidelines of Prostate Cancer Clinical Trials Working Group 2 (PCWG2).For participants with PSA decline at Week 13, the PSA progression date was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which would be confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at Week 13, the PSA progression date was defined as the date when a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later. Time to PSA progression was estimated using the Kaplan-Meier method. Participants without confirmed PSA progression were censored.

    Time frame: From the date of randomization to PSA progression median follow-up time is 6.47 months for enzalutamide and 2.99 months for placebo

Secondary outcomes

  1. Duration of Overall Survival

    Duration of overall survival was defined as the time from the randomization to deaths from any cause. For participants who were alive at the time of the data analysis, overall survival time was censored to the last know date the participants were known to be alive.

    Time frame: From the date of randomization to deaths from any cause median follow-up time is 42.32 months for enzalutamide and 26.81 months for placebo

  2. Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment

    Duration of Radiographic Progression-free Survival (rPFS) was defined as the time from randomization to the rPFS event (deaths from any cause and radiographic disease progression). Radiographic disease progression is defined by RECIST 1.1 for soft tissue disease, or PCWG2 for bone lesions. If a participant met the criteria for more than 1 censoring rule, they were censored with the earliest censoring date. The radiographic progression date was the first date when progression definition was met, not confirmed.

    Time frame: From the date of randomization to the rPFS event (deaths from any cause and radiographic disease progression) median follow-up time is 5.55 months for enzalutamide and 3.71 months for placebo

  3. Time to First Skeletal-Related Event

    Time to first skeletal-related event (SRE) was defined as the time from randomization to the first skeletal-related event, defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of anti-neoplastic therapy to treat bone pain. Participants who have not had a SRE at the time of the analysis were censored at their last assessment indicating no evidence of SRE.

    Time frame: From the date of randomization to the first skeletal-related event median follow-up time is 7.39 months for enzalutamide and 5.29 months for placebo

  4. Time to Initiation of Cytotoxic Chemotherapy

    Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to initiation of cytotoxic chemotherapy. It included only therapies for prostate cancer. When multiple cytotoxic chemotherapies were initiated, the first chemotherapy was used to determine the time to event. Participants who did not start cytotoxic chemotherapy at the time of analysis data cutoff were censored at the date of their last assessment indicating no evidence of cytotoxic chemotherapy usage.

    Time frame: From the date of randomization to initiation of cytotoxic chemotherapy median follow-up time is 7.39 months for enzalutamide and 5.19 months for placebo

  5. Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)

    Best PSA response was defined as as ≥50% reductions in PSA level from baseline to the lowest post-baseline PSA result as determined by the central laboratory, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response. Only participants who had both baseline and post-baseline assessments were included in the analysis.

    Time frame: From baseline to the lowest post-baseline PSA result median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo

  6. Best Overall Soft Tissue Response

    Participants with measurable soft tissue disease at screening visit (i.e., at least one target lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) who have an objective response (complete response (CR) or partial response (PR)) during the study were included in the best overall soft tissue response assessment. The best overall soft tissue response was based on the investigator assessment using RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

    Time frame: From the date of randomization median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo

  7. Time to Maximum Concentration (Tmax) of Enzalutamide, M1,M2 and Enzalutamide Plus M2

    Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85

  8. Maximum Observed Plasma Concentration During the First 24 Hours After Dosing (Cmax) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85

  9. AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85

  10. Concentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    N is the number of participants with available data at this time point.

    Time frame: From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85

  11. Observed Plasma Concentration in Predose Samples Obtained During Multiple-dose Administration of Minimum Concentration (Plasma Concentration at Pre Dose) (Cmin) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    N is the number of participants with available data at this time point.

    Time frame: From the date of randomization up to Days 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169

  12. Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)

    Time frame: From the date of randomization up to Multiple Dosing Day 85

  13. Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    Time frame: From the date of randomization up to Multiple Dosing Day 85

  14. AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2

    Time frame: From the date of randomization up to Multiple Dosing Day 85

  15. Number of Participants With Adverse Events (AE)

    An AE was defined as any untoward medical occurrence, temporally associated with use of medicinal product, whether considered related to medicinal product. AE could therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with use of a medicinal product. An AE was considered serious if, results in death; is life-threatening; results in persistent disability; results in congenital anomaly; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as AE occurring from time of study drug administration on Day 1 until follow-up visit (28 days after last dose, or one day before date of initiation of cytotoxic chemotherapy or an investigational agent, whichever comes first). AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.

    Time frame: From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days

07

Results

Posted Apr 12, 2017

Participant flow

The study population consisted of men with asymptomatic or mildly symptomatic progressive metastatic prostate cancer, who had failed androgen deprivation therapy, and have not been treated with cytotoxic chemotherapy. Participants from 46 study sites in 4 countries (China, Korea, Taiwan and Hong Kong) were randomized for the study.

Double-blind Period (up to 29.4 Months)
Participant flow — Double-blind Period (up to 29.4 Months)
MilestoneEnzalutamidePlaceboPlacebo Patients Crossover to Enzalutamide 160 mg
Started2021930
Treated/received study drug2021930
Completed8410
Not completed1181920
Withdrew: Death640
Withdrew: Miscellaneous30660
Withdrew: Withdrawal by subject27540
Withdrew: Protocol deviation020
Withdrew: Lost to follow-up100
Withdrew: Progressive disease38510
Withdrew: Adverse event16150
Open-label Period (up to 54.3 Months)
Participant flow — Open-label Period (up to 54.3 Months)
MilestoneEnzalutamidePlaceboPlacebo Patients Crossover to Enzalutamide 160 mg
Started85051
Completed000
Not completed85051
Withdrew: Miscellaneous28016
Withdrew: Withdrawal by subject19010
Withdrew: Protocol deviation200
Withdrew: Lost to follow-up402
Withdrew: Progressive disease20012
Withdrew: Death605
Withdrew: Adverse event606

Outcome measures

PrimaryTime to Prostate-specific Antigen (PSA) Progression

The time to Prostate Specific Antigen (PSA) progression was defined as the time from randomization to the PSA progression. The PSA progression was defined according to the consensus guidelines of Prostate Cancer Clinical Trials Working Group 2 (PCWG2).For participants with PSA decline at Week 13, the PSA progression date was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir, which would be confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at Week 13, the PSA progression date was defined as the date when a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later. Time to PSA progression was estimated using the Kaplan-Meier method. Participants without confirmed PSA progression were censored.

Time frame:
From the date of randomization to PSA progression median follow-up time is 6.47 months for enzalutamide and 2.99 months for placebo
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsEnzalutamidePlacebo
Time to Prostate-specific Antigen (PSA) Progression8.31 (5.72 to 10.25)2.86 (2.83 to 4.63)
Statistical analysis
  • Enzalutamide vs Placebo · Hazard Ratio · p = <0.0001 · Unstratified cox proportional hazards: 0.38 · 95% CI 0.27 to 0.52
SecondaryDuration of Overall Survival

Duration of overall survival was defined as the time from the randomization to deaths from any cause. For participants who were alive at the time of the data analysis, overall survival time was censored to the last know date the participants were known to be alive.

Time frame:
From the date of randomization to deaths from any cause median follow-up time is 42.32 months for enzalutamide and 26.81 months for placebo
Reported as:
Median · Months
Duration of Overall Survival
MonthsEnzalutamidePlacebo
Duration of Overall Survival39.06 (29.24 to 57.63)27.10 (21.88 to 37.82)
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified log-rank test · p = 0.0208 (P-value is based on an unstratified log-rank test.) · Hazard ratio (hr): 0.70 · 95% CI 0.51 to 0.95
SecondaryDuration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment

Duration of Radiographic Progression-free Survival (rPFS) was defined as the time from randomization to the rPFS event (deaths from any cause and radiographic disease progression). Radiographic disease progression is defined by RECIST 1.1 for soft tissue disease, or PCWG2 for bone lesions. If a participant met the criteria for more than 1 censoring rule, they were censored with the earliest censoring date. The radiographic progression date was the first date when progression definition was met, not confirmed.

Time frame:
From the date of randomization to the rPFS event (deaths from any cause and radiographic disease progression) median follow-up time is 5.55 months for enzalutamide and 3.71 months for placebo
Reported as:
Median · Months
Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility Assessment
MonthsEnzalutamidePlacebo
Duration of Radiographic Progression-free Survival (rPFS) Based on Independent Central Review Facility AssessmentNA (10.97 to NA)5.29 (3.61 to 11.33)
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified log-rank test · p = <0.0001 (P-value is based on an unstratified log-rank test.) · Hazard ratio (hr): 0.31 · 95% CI 0.20 to 0.46
SecondaryTime to First Skeletal-Related Event

Time to first skeletal-related event (SRE) was defined as the time from randomization to the first skeletal-related event, defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of anti-neoplastic therapy to treat bone pain. Participants who have not had a SRE at the time of the analysis were censored at their last assessment indicating no evidence of SRE.

Time frame:
From the date of randomization to the first skeletal-related event median follow-up time is 7.39 months for enzalutamide and 5.29 months for placebo
Reported as:
Median · Months
Time to First Skeletal-Related Event
MonthsEnzalutamidePlacebo
Time to First Skeletal-Related EventNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified log-rank test · p = 0.2501 (P-value was based on an unstratified log-rank test.) · Hazard ratio (hr): 0.56 · 95% CI 0.21 to 1.52
SecondaryTime to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy was defined as the time from randomization to initiation of cytotoxic chemotherapy. It included only therapies for prostate cancer. When multiple cytotoxic chemotherapies were initiated, the first chemotherapy was used to determine the time to event. Participants who did not start cytotoxic chemotherapy at the time of analysis data cutoff were censored at the date of their last assessment indicating no evidence of cytotoxic chemotherapy usage.

Time frame:
From the date of randomization to initiation of cytotoxic chemotherapy median follow-up time is 7.39 months for enzalutamide and 5.19 months for placebo
Reported as:
Median · Months
Time to Initiation of Cytotoxic Chemotherapy
MonthsEnzalutamidePlacebo
Time to Initiation of Cytotoxic ChemotherapyNA (NA to NA)13.93 (NA to NA)
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified log-rank test · p = 0.0020 (P-value is based on an unstratified log-rank test.) · Hazard ratio (hr): 0.28 · 95% CI 0.12 to 0.66
SecondaryNumber of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)

Best PSA response was defined as as ≥50% reductions in PSA level from baseline to the lowest post-baseline PSA result as determined by the central laboratory, with a consecutive assessment conducted at least 3 weeks later to confirm the PSA response. Only participants who had both baseline and post-baseline assessments were included in the analysis.

Time frame:
From baseline to the lowest post-baseline PSA result median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
Reported as:
Number · Participants
Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)
ParticipantsEnzalutamidePlacebo
Number of Participants With Confirmed Best PSA Response (≥50% Decrease From Baseline)12015
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified Cochran-Mantel-Haenszel % · p = <0.0001 (P-value is based on unstratified Cochran-Mantel-Haenszel mean score test.) · Difference of response rate: 55.8 · 95% CI 47.4 to 64.2
SecondaryBest Overall Soft Tissue Response

Participants with measurable soft tissue disease at screening visit (i.e., at least one target lesion per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) who have an objective response (complete response (CR) or partial response (PR)) during the study were included in the best overall soft tissue response assessment. The best overall soft tissue response was based on the investigator assessment using RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

Time frame:
From the date of randomization median treatment duration is 6.60 months for enzalutamide and 3.70 months for placebo
Reported as:
Number · Participants
Best Overall Soft Tissue Response
ParticipantsEnzalutamidePlacebo
Best Overall Soft Tissue Response181
Statistical analysis
  • Enzalutamide vs Placebo · Unstratified Cochran-Mantel-Haenszel · p = <0.0001 (P-value is based on unstratified Cochran-Mantel-Haenszel mean score test.) · Difference in objective response rate: 26.0 · 95% CI 14.7 to 37.4
SecondaryTime to Maximum Concentration (Tmax) of Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame:
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Reported as:
Median · hour
Time to Maximum Concentration (Tmax) of Enzalutamide, M1,M2 and Enzalutamide Plus M2
hourEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Day 10.975 (0.500 to 6.05)24.0 (0.550 to 24.9)24.0 (0.550 to 24.9)0.975 (0.500 to 24.0)
Day 851.00 (0 to 2.00)1.02 (0.217 to 24.1)0 (0 to 23.8)0.250 (0 to 23.8)
SecondaryMaximum Observed Plasma Concentration During the First 24 Hours After Dosing (Cmax) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame:
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Reported as:
Mean · micrograms/milliliter (μg/mL)
Maximum Observed Plasma Concentration During the First 24 Hours After Dosing (Cmax) Enzalutamide, M1,M2 and Enzalutamide Plus M2
micrograms/milliliter (μg/mL)EnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Day 13.92 ± 1.370.112 ± 0.07940.175 ± 0.09213.94 ± 1.34
Day 8520.0 ± 3.2214.0 ± 23.515.2 ± 3.4434.2 ± 4.98
SecondaryAUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame:
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Reported as:
Mean · μg*h/mL
AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
μg*h/mLEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
AUC From the Time of Dosing to 24 h After Dosing (AUC24h) Enzalutamide, M1,M2 and Enzalutamide Plus M243.1 ± 9.641.81 ± 0.9722.17 ± 1.3045.3 ± 10.1
SecondaryConcentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2

N is the number of participants with available data at this time point.

Time frame:
From the date of randomization, Single Dosing Day 1 and Multiple Dosing Day 85
Reported as:
Mean · μg/mL
Concentration 24 h After Dosing (C24h) Enzalutamide, M1,M2 and Enzalutamide Plus M2
μg/mLEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Day 11.65 ± 0.3430.111 ± 0.08010.164 ± 0.09421.82 ± 0.363
Day 8517.6 ± 3.096.09 ± 3.0713.7 ± 2.9131.2 ± 4.00
SecondaryObserved Plasma Concentration in Predose Samples Obtained During Multiple-dose Administration of Minimum Concentration (Plasma Concentration at Pre Dose) (Cmin) Enzalutamide, M1,M2 and Enzalutamide Plus M2

N is the number of participants with available data at this time point.

Time frame:
From the date of randomization up to Days 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169
Reported as:
Mean · μg/mL
Observed Plasma Concentration in Predose Samples Obtained During Multiple-dose Administration of Minimum Concentration (Plasma Concentration at Pre Dose) (Cmin) Enzalutamide, M1,M2 and Enzalutamide Plus M2
μg/mLEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Day 2 predose1.65 ± 0.3430.111 ± 0.08010.164 ± 0.09421.82 ± 0.363
Day 3 predose3.29 ± 1.160.302 ± 0.2560.367 ± 0.1883.66 ± 1.24
Day 8 predose9.39 ± 2.071.21 ± 0.9231.94 ± 0.98311.3 ± 2.62
Day 22 predose17.6 ± 2.376.09 ± 8.268.34 ± 2.7425.9 ± 3.25
Day 29 predose19.6 ± 4.008.16 ± 12.510.9 ± 3.7230.5 ± 5.47
Day 43 predose17.0 ± 4.1312.5 ± 22.114.0 ± 3.9931.0 ± 5.82
Day 57 predose17.8 ± 3.0918.4 ± 28.214.7 ± 3.8832.5 ± 4.57
Day 85 predose17.9 ± 3.196.33 ± 2.9514.9 ± 3.6732.8 ± 5.10
Day 86 predose17.6 ± 3.096.09 ± 3.0713.7 ± 2.9131.2 ± 4.00
Day 113 predose17.5 ± 4.1417.5 ± 33.115.0 ± 3.2132.5 ± 3.72
Day 141 predose17.3 ± 3.735.52 ± 2.1014.3 ± 3.9031.6 ± 4.70
Day 169 predose17.2 ± 5.555.09 ± 2.2714.0 ± 4.8031.2 ± 5.02
SecondaryApparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)
Time frame:
From the date of randomization up to Multiple Dosing Day 85
Reported as:
Mean · L/h
Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)
L/hEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Apparent Total Systemic Clearance After Multiple Dosing (CL/F) Enzalutamide, M1,M2 and Enzalutamide Plus M2 (For Unchanged Enzalutamide Only)0.387 ± 0.0774NA ± NANA ± NANA ± NA
SecondaryPeak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame:
From the date of randomization up to Multiple Dosing Day 85
Reported as:
Mean · Ratio
Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M2
RatioEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
Peak-Trough Ratio (PTR) Enzalutamide, M1,M2 and Enzalutamide Plus M21.15 ± 0.1101.19 ± 0.3641.09 ± 0.08971.08 ± 0.0581
SecondaryAUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2
Time frame:
From the date of randomization up to Multiple Dosing Day 85
Reported as:
Mean · μg*h/mL
AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2
μg*h/mLEnzalutamideM1- Carboxylic Acid MetaboliteM2- N-Desmethyl EnzalutamideEnzalutamide Plus M2
AUC From the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) Enzalutamide, M1,M2 and Enzalutamide Plus M2427 ± 79.8149 ± 74.1308 ± 68.2735 ± 109
SecondaryNumber of Participants With Adverse Events (AE)

An AE was defined as any untoward medical occurrence, temporally associated with use of medicinal product, whether considered related to medicinal product. AE could therefore be any unfavorable \& unintended sign, symptom, or disease temporally associated with use of a medicinal product. An AE was considered serious if, results in death; is life-threatening; results in persistent disability; results in congenital anomaly; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as AE occurring from time of study drug administration on Day 1 until follow-up visit (28 days after last dose, or one day before date of initiation of cytotoxic chemotherapy or an investigational agent, whichever comes first). AEs were graded using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening; Grade 5 = Fatal.

Time frame:
From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE)
ParticipantsEnzalutamidePlaceboPlacebo Followed by Enzalutamide
Treatment Emergent Adverse Events (TEAEs)19016647
Grade 3 or Higher TEAE986628
TEAE Leading to Death2477
Serious TEAE875724
TEAE That Was Primary Reason for Treatment Discontinuation32337
TEAE Leading to Study Drug Discontinuation494212
TEAE Leading to Dose Reduction of Study Drug432
TEAE Leading to Dose Interruption of Study Drug28167
TEAE Related to Study Drug1025913
Grade 3 or Higher TEAE Related to Study Drug26135
Serious TEAE Related to Study Drug1473

Adverse events

Collected over All cause mortality: From the date of randomization up to 123 months and 24 days AE: From first dose on Day 1 until 28 days after the last dose of study drug, or one day before the date of initiation of cytotoxic chemotherapy or an investigational agent for treatment of prostate cancer, whichever comes first, up to 123 months and 24 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide85/202 (42.1%)87/202 (43.1%)169/202 (83.7%)
Placebo57/193 (29.5%)57/193 (29.5%)125/193 (64.8%)
Placebo Patients Crossover to Enzalutamide 160 mg21/51 (41.2%)24/51 (47.1%)31/51 (60.8%)
Most frequent serious events
Showing 10 of 175
Most frequent serious events
EventEnzalutamidePlaceboPlacebo Patients Crossover to Enzalutamide 160 mg
PneumoniaInfections and infestations16/2020/1933/51
HaematuriaRenal and urinary disorders8/2026/1930/51
CataractEye disorders2/2020/1932/51
NauseaGastrointestinal disorders0/2020/1932/51
VomitingGastrointestinal disorders0/2020/1932/51
Septic shockInfections and infestations2/2021/1932/51
Spinal compression fractureInjury, poisoning and procedural complications1/2020/1932/51
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2020/1932/51
HydronephrosisRenal and urinary disorders3/2021/1932/51
Urinary retentionRenal and urinary disorders7/2022/1931/51
Most frequent other events
Showing 10 of 28
Most frequent other events
EventEnzalutamidePlaceboPlacebo Patients Crossover to Enzalutamide 160 mg
AnaemiaBlood and lymphatic system disorders30/20216/19310/51
Decreased appetiteMetabolism and nutrition disorders37/20219/1936/51
Back painMusculoskeletal and connective tissue disorders37/20219/1935/51
FatigueGeneral disorders29/20215/1933/51
ConstipationGastrointestinal disorders27/20215/1933/51
ArthralgiaMusculoskeletal and connective tissue disorders26/20212/1931/51
Bone painMusculoskeletal and connective tissue disorders19/20224/1931/51
Pain in extremityMusculoskeletal and connective tissue disorders24/20217/1930/51
Upper respiratory tract infectionInfections and infestations13/2025/1936/51
NauseaGastrointestinal disorders23/20211/1932/51

Baseline characteristics

Intent-to-treat (ITT) population consisted of all randomized participants in the study.

Age, Continuous
Age, Continuous(Years)EnzalutamidePlaceboTotal
Mean71.6 ± 8.171 ± 8.771.3 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)EnzalutamidePlaceboTotal
Female000
Male202193395
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EnzalutamidePlaceboTotal
American Indian or Alaska Native000
Asian202193395
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)EnzalutamidePlaceboTotal
Count of participants——0
08

Study locations

47 sites
  • CN00103
    Beijing, China
  • CN00104
    Beijing, China
  • CN00106
    Beijing, China
  • CN00111
    Beijing, China
  • CN00112
    Beijing, China
  • CN00114
    Beijing, China
  • CN00115
    Beijing, China
  • CN00127
    Beijing, China
  • CN00121
    Changsha, China
  • CN00107
    Hangzhou, China
  • CN00110
    Nanjing, China
  • CN00117
    Nanjing, China
  • CN00102
    Shanghai, China
  • CN00105
    Shanghai, China
  • CN00108
    Shanghai, China
  • CN00113
    Shanghai, China
  • CN00126
    Shanghai, China
  • CN00119
    Suzhou, China
  • CN00125
    Tianjin, China
  • CN00118
    Wenzhou, China
  • CN00109
    Wuhan, China
  • CN00124
    Xi'an, China
  • HK00402
    Hong Kong, Hong Kong
  • KR00214
    Anyang, South Korea
  • KR00205
    Busan, South Korea
  • KR00207
    Busan, South Korea
  • KR00212
    Cheongju-si, South Korea
  • KR00203
    Daegu, South Korea
  • KR00213
    Daejeon, South Korea
  • KR00201
    Incheon, South Korea
  • KR00202
    Seongnam-si, South Korea
  • KR00204
    Seoul, South Korea
  • KR00206
    Seoul, South Korea
  • KR00208
    Seoul, South Korea
  • KR00209
    Seoul, South Korea
  • KR00210
    Seoul, South Korea
  • KR00211
    Seoul, South Korea
  • KR00215
    Seoul, South Korea
  • TW00309
    Kaohsiung City, Taiwan
  • TW00302
    Taichung, Taiwan
  • TW00303
    Taichung, Taiwan
  • TW00307
    Tainan, Taiwan
  • TW00308
    Tainan, Taiwan
  • TW00301
    Taipei, Taiwan
  • TW00304
    Taipei, Taiwan
  • TW00306
    Taipei, Taiwan
  • TW00305
    Taoyuan County, Taiwan
09

References and documents

Publications

  • Pu YS, Ahn H, Han W, Huang SP, Wu HC, Ma L, Yamada S, Suga K, Xie LP. Enzalutamide in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Adv Ther. 2022 Jun;39(6):2641-2656. doi: 10.1007/s12325-022-02140-2. Epub 2022 Apr 10. PubMed 35397772 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Sep 2015, 16 months.

Results were first posted in Apr 2017, 1 year 6 months after primary completion. A results delay was requested in Sep 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Nov 19, 2014
StartActual
Apr 23, 2014
Primary completionActual
Sep 20, 2015
CompletionActual
Jul 17, 2024
Results delay requested
Sep 1, 2016
Results first posted
Apr 12, 2017
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02294461
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Apr 23, 2014
Primary completion
Sep 20, 2015
Completion
Jul 17, 2024
Results posted
Apr 12, 2017
Last update
Oct 24, 2025

Study contacts

Central Contact
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion